A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in the 2007-2008 Influenza Season in Healthy Adult Subjects.

Trial Profile

A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in the 2007-2008 Influenza Season in Healthy Adult Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2013

At a glance

  • Drugs Influenza vaccine (Optaflu) (Primary) ; Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 21 Nov 2012 Results from this trial supported US FDA approval of the Flucelvax influenza vaccine.
    • 14 Feb 2011 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 24 Sep 2010 Primary endpoint 'Vaccine-protective-efficacy' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top